What is Leerink Partnrs' Forecast for PTCT FY2026 Earnings?

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Equities researchers at Leerink Partnrs raised their FY2026 EPS estimates for shares of PTC Therapeutics in a note issued to investors on Tuesday, April 29th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will earn ($2.58) per share for the year, up from their prior forecast of ($4.74). The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share.

Several other research firms have also issued reports on PTCT. Citigroup lifted their target price on shares of PTC Therapeutics from $32.00 to $45.00 and gave the company a "sell" rating in a report on Wednesday, February 12th. Morgan Stanley reiterated an "overweight" rating and set a $70.00 price objective (up previously from $67.00) on shares of PTC Therapeutics in a research note on Friday, March 7th. Scotiabank initiated coverage on PTC Therapeutics in a research note on Friday, March 7th. They issued a "sector perform" rating and a $55.00 target price on the stock. JPMorgan Chase & Co. lowered their price target on PTC Therapeutics from $78.00 to $75.00 and set an "overweight" rating for the company in a research report on Monday, March 31st. Finally, StockNews.com downgraded shares of PTC Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $63.92.

PTC Therapeutics Price Performance

NASDAQ:PTCT traded up $0.43 during mid-day trading on Thursday, hitting $49.95. 984,809 shares of the company's stock were exchanged, compared to its average volume of 803,026. The company has a market cap of $3.94 billion, a PE ratio of -8.41 and a beta of 0.52. PTC Therapeutics has a one year low of $28.72 and a one year high of $58.38. The business has a fifty day moving average price of $50.00 and a 200 day moving average price of $46.97.

Insider Activity at PTC Therapeutics

In other PTC Therapeutics news, CAO Christine Marie Utter sold 879 shares of the firm's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total value of $44,037.90. Following the transaction, the chief accounting officer now directly owns 63,442 shares of the company's stock, valued at approximately $3,178,444.20. This trade represents a 1.37 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Mark Elliott Boulding sold 1,333 shares of the company's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total transaction of $66,783.30. Following the sale, the vice president now directly owns 105,515 shares of the company's stock, valued at $5,286,301.50. The trade was a 1.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,305 shares of company stock worth $1,682,755 over the last quarter. Company insiders own 5.50% of the company's stock.

Institutional Investors Weigh In On PTC Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vontobel Holding Ltd. purchased a new stake in PTC Therapeutics during the 4th quarter valued at approximately $521,000. Raymond James Financial Inc. purchased a new stake in PTC Therapeutics in the 4th quarter worth $2,200,000. Natixis Advisors LLC purchased a new stake in PTC Therapeutics in the 4th quarter worth $544,000. Proficio Capital Partners LLC purchased a new position in shares of PTC Therapeutics during the fourth quarter valued at about $758,000. Finally, American Century Companies Inc. lifted its position in shares of PTC Therapeutics by 66.8% in the fourth quarter. American Century Companies Inc. now owns 60,150 shares of the biopharmaceutical company's stock worth $2,715,000 after buying an additional 24,090 shares in the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.